Eagle Pharmaceuticals Inc.
| NASDAQ: EGRX | Healthcare / Drug Manufacturers / USA |
| 14.46 | +0.1800 | +1.26% | Vol 159.45K | 1Y Perf -47.09% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 13.64 | ASK | 15.13 | ||
| Open | 14.28 | Previous Close | 14.28 | ||
| Pre-Market | - | After-Market | 14.72 | ||
| - - | 0.26 1.80% |
| Target Price | 39.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 169.71 | Finscreener Ranking | ★★★★ 53.60 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 54.27 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★ 58.11 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.46 | Earnings Rating | Strong Buy | |
| Market Cap | 187.79M | Earnings Date | 6th Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.11 | |
| Beta | 0.91 |
Today's Price Range 14.0914.51 | 52W Range 14.0740.85 | 5 Year PE Ratio Range 9.1067.00 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.35% | ||
| 1 Month | -17.28% | ||
| 3 Months | -27.48% | ||
| 6 Months | -53.71% | ||
| 1 Year | -47.09% | ||
| 3 Years | -66.27% | ||
| 5 Years | -77.81% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 2.00 | |||
ROE last 12 Months | 10.95 | |||
ROA (5Y Avg) | 1.17 | |||
ROA last 12 Months | 7.05 | |||
ROC (5Y Avg) | 10.14 | |||
ROC last 12 Months | 8.87 | |||
Return on invested Capital Q | -0.87 | |||
Return on invested Capital Y | -2.85 | |||
Assets Turnover | 0.80 | |||
Receivables Turnover | 3.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 18.30 | ||||
| 1.71 | ||||
| 1.56 | ||||
| 18.70 | ||||
| -6.50 | ||||
| 1.63 | ||||
| 4.88 | ||||
| 17.81 | ||||
| 445.85M | ||||
| Forward PE | 35.84 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.90 | ||||
| 1.50 | ||||
| 0.10 | ||||
| 0.26 | ||||
| 20.70 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 70.70 | ||||
| 17.40 | ||||
| 19.90 | ||||
| 14.60 | ||||
| 10.74 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 255.91M | ||||
| 19.66 | ||||
| -3.07 | ||||
| -4.98 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | 0.44 | 0.39 | -11.36 |
| Q01 2023 | 0.40 | 0.44 | 10.00 |
| Q04 2022 | -0.54 | 0.62 | 214.81 |
| Q03 2022 | 0.23 | -0.27 | -217.39 |
| Q02 2022 | 2.48 | -0.74 | -129.84 |
| Q01 2022 | 3.19 | 3.41 | 6.90 |
| Q04 2021 | 0.41 | -0.48 | -217.07 |
| Q03 2021 | -0.44 | -0.43 | 2.27 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | 0.40 | 33.33 | Positive |
| 12/2023 QR | 0.42 | 180.00 | Positive |
| 12/2023 FY | 1.65 | 27.91 | Positive |
| 12/2024 FY | 0.44 | 331.58 | Positive |
| Next Report Date | 6th Nov 2023 |
| Estimated EPS Next Report | 0.40 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 159.45K |
| Shares Outstanding | 12.99K |
| Shares Float | 11.45M |
| Trades Count | 3.13K |
| Dollar Volume | 2.28M |
| Avg. Volume | 103.65K |
| Avg. Weekly Volume | 97.22K |
| Avg. Monthly Volume | 89.19K |
| Avg. Quarterly Volume | 124.54K |
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) stock closed at 14.46 per share at the end of the most recent trading day (a 1.26% change compared to the prior day closing price) with a volume of 159.45K shares and market capitalization of 187.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 108 people. Eagle Pharmaceuticals Inc. CEO is Scott L. Tarriff.
The one-year performance of Eagle Pharmaceuticals Inc. stock is -47.09%, while year-to-date (YTD) performance is -50.53%. EGRX stock has a five-year performance of -77.81%. Its 52-week range is between 14.07 and 40.85, which gives EGRX stock a 52-week price range ratio of 1.46%
Eagle Pharmaceuticals Inc. currently has a PE ratio of 18.30, a price-to-book (PB) ratio of 1.71, a price-to-sale (PS) ratio of 1.56, a price to cashflow ratio of 18.70, a PEG ratio of -, a ROA of 7.05%, a ROC of 8.87% and a ROE of 10.95%. The company’s profit margin is 10.74%, its EBITDA margin is 19.90%, and its revenue ttm is $255.91 Million , which makes it $19.66 revenue per share.
Of the last four earnings reports from Eagle Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.40 for the next earnings report. Eagle Pharmaceuticals Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Eagle Pharmaceuticals Inc. is Strong Buy (1), with a target price of $39, which is +169.71% compared to the current price. The earnings rating for Eagle Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eagle Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eagle Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.28, ATR14 : 0.70, CCI20 : -181.24, Chaikin Money Flow : -0.03, MACD : -0.70, Money Flow Index : 18.91, ROC : -8.83, RSI : 33.94, STOCH (14,3) : 13.76, STOCH RSI : 0.21, UO : 44.44, Williams %R : -86.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eagle Pharmaceuticals Inc. in the last 12-months were: Tarriff Scott (Sold 60 000 shares of value $1 230 356 )
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.
CEO: Scott L. Tarriff
Telephone: +1 201 326-5300
Address: 50 Tice Boulevard, Woodcliff Lake 07677, NJ, US
Number of employees: 108
